JP2024028453A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024028453A5 JP2024028453A5 JP2024002413A JP2024002413A JP2024028453A5 JP 2024028453 A5 JP2024028453 A5 JP 2024028453A5 JP 2024002413 A JP2024002413 A JP 2024002413A JP 2024002413 A JP2024002413 A JP 2024002413A JP 2024028453 A5 JP2024028453 A5 JP 2024028453A5
- Authority
- JP
- Japan
- Prior art keywords
- pharma
- acceptable salt
- ceutically acceptable
- rnai agent
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 5
- 108091030071 RNAI Proteins 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 230000009368 gene silencing by RNA Effects 0.000 claims 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 2
- 125000005647 linker group Chemical group 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000000732 arylene group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 125000002993 cycloalkylene group Chemical group 0.000 claims 1
- SXADIBFZNXBEGI-UHFFFAOYSA-N phosphoramidous acid Chemical group NP(O)O SXADIBFZNXBEGI-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862631683P | 2018-02-17 | 2018-02-17 | |
| US62/631,683 | 2018-02-17 | ||
| US201862646739P | 2018-03-22 | 2018-03-22 | |
| US62/646,739 | 2018-03-22 | ||
| US201862663763P | 2018-04-27 | 2018-04-27 | |
| US62/663,763 | 2018-04-27 | ||
| US201962790300P | 2019-01-09 | 2019-01-09 | |
| US62/790,300 | 2019-01-09 | ||
| JP2020543533A JP7420727B2 (ja) | 2018-02-17 | 2019-02-15 | トリアルキン結合剤及び使用方法 |
| PCT/US2019/018232 WO2019161213A1 (en) | 2018-02-17 | 2019-02-15 | Trialkyne linking agents and methods of use |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543533A Division JP7420727B2 (ja) | 2018-02-17 | 2019-02-15 | トリアルキン結合剤及び使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024028453A JP2024028453A (ja) | 2024-03-04 |
| JP2024028453A5 true JP2024028453A5 (enExample) | 2024-10-21 |
Family
ID=67620056
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543533A Active JP7420727B2 (ja) | 2018-02-17 | 2019-02-15 | トリアルキン結合剤及び使用方法 |
| JP2024002413A Pending JP2024028453A (ja) | 2018-02-17 | 2024-01-11 | トリアルキン結合剤及び使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543533A Active JP7420727B2 (ja) | 2018-02-17 | 2019-02-15 | トリアルキン結合剤及び使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250092072A1 (enExample) |
| EP (1) | EP3752166A4 (enExample) |
| JP (2) | JP7420727B2 (enExample) |
| CN (2) | CN111698995B (enExample) |
| AU (2) | AU2019220739B2 (enExample) |
| CA (1) | CA3089276A1 (enExample) |
| IL (1) | IL276687B2 (enExample) |
| WO (1) | WO2019161213A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10590416B2 (en) * | 2017-07-06 | 2020-03-17 | Arrowhead Pharmaceuticals, Inc. | RNAi agents for inhibiting expression of alpha-ENaC and methods of use |
| CA3120580A1 (en) | 2019-01-09 | 2020-07-16 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for inhibiting expression of hif-2 alpha (epas1), compositions thereof, and methods of use |
| KR20220024153A (ko) | 2019-05-24 | 2022-03-03 | 엠피리코 인크. | 안지오포이에틴 유사 7(angptl7) 관련 질환의 치료 |
| CA3152529A1 (en) * | 2019-09-03 | 2021-03-11 | Arcturus Therapeutics, Inc. | Asialoglycoprotein receptor mediated delivery of therapeutically active conjugates |
| JP2023541427A (ja) * | 2020-09-11 | 2023-10-02 | アローヘッド ファーマシューティカルズ インコーポレイテッド | 骨格筋送達プラットフォーム及び使用方法 |
| UY39417A (es) * | 2020-09-11 | 2022-03-31 | Arrowhead Pharmaceuticals Inc | Agentes de arni para inhibir la expresión de dux4, composiciones de dichos agentes, y métodos de uso |
| WO2022216920A1 (en) | 2021-04-08 | 2022-10-13 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use |
| IL308883A (en) | 2021-05-28 | 2024-01-01 | Arrowhead Pharmaceuticals Inc | RNAi AGENTS FOR INHIBITING EXPRESSION OF MUCIN 5AC (MUC5AC), COMPOSITIONS THEREOF, AND METHODS OF USE |
| CN113956206B (zh) * | 2021-10-25 | 2023-04-28 | 深圳湾实验室坪山生物医药研发转化中心 | 一种用于修饰蛋白质赖氨酸残基的探针及其制备方法 |
| EP4499111A2 (en) * | 2022-03-28 | 2025-02-05 | Empirico Inc. | Compositions and methods for the treatment of angiopoietin like 7 (angptl7) related diseases |
| CA3246872A1 (en) * | 2022-03-28 | 2023-10-05 | Empirico Inc. | MODIFIED OLIGONUCLEOTIDES |
| US11912997B2 (en) | 2022-06-15 | 2024-02-27 | Arrowhead Pharmaceuticals, Inc. | RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use |
| AU2023399039A1 (en) * | 2022-12-14 | 2025-05-22 | Alnylam Pharmaceuticals, Inc. | ALPHA-V BETA-6(ανβ6) INTEGRIN LIGANDS FOR EXTRAHEPATIC DELIVERY |
| US12442002B2 (en) | 2023-12-20 | 2025-10-14 | Arrowhead Pharmaceuticals, Inc. | RNAi agents for inhibiting expression of activin receptor-like kinase 7 (ALK7), compositions thereof, and methods of use |
| WO2025152969A1 (zh) * | 2024-01-15 | 2025-07-24 | 武汉人福创新药物研发中心有限公司 | 靶向化合物及其用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2650668A1 (en) * | 2006-04-28 | 2007-11-08 | Centre National De La Recherche Scientifique | Method for the synthesis of triazole-containing oligonucleotide deratives |
| GB201313201D0 (en) * | 2013-07-24 | 2013-09-04 | Univ East Anglia | Virus Detection |
| ES2742102T3 (es) | 2014-01-15 | 2020-02-13 | Baseclick Gmbh | Moléculas de ácido nucleico modificadas con sacárido |
| CA2985823A1 (en) * | 2015-05-12 | 2016-11-17 | Blinkbio, Inc. | Silicon based drug conjugates and methods of using same |
| WO2018013525A1 (en) * | 2016-07-11 | 2018-01-18 | Translate Bio Ma, Inc. | Nucleic acid conjugates and uses thereof |
| US10590416B2 (en) * | 2017-07-06 | 2020-03-17 | Arrowhead Pharmaceuticals, Inc. | RNAi agents for inhibiting expression of alpha-ENaC and methods of use |
-
2019
- 2019-02-15 CN CN201980013763.0A patent/CN111698995B/zh active Active
- 2019-02-15 CN CN202510149001.0A patent/CN120247964A/zh active Pending
- 2019-02-15 JP JP2020543533A patent/JP7420727B2/ja active Active
- 2019-02-15 EP EP19754398.6A patent/EP3752166A4/en active Pending
- 2019-02-15 CA CA3089276A patent/CA3089276A1/en active Pending
- 2019-02-15 AU AU2019220739A patent/AU2019220739B2/en active Active
- 2019-02-15 WO PCT/US2019/018232 patent/WO2019161213A1/en not_active Ceased
- 2019-02-15 IL IL276687A patent/IL276687B2/en unknown
-
2024
- 2024-01-11 JP JP2024002413A patent/JP2024028453A/ja active Pending
- 2024-07-16 US US18/773,657 patent/US20250092072A1/en active Pending
-
2025
- 2025-11-12 AU AU2025267360A patent/AU2025267360A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024028453A5 (enExample) | ||
| JP2023171659A5 (enExample) | ||
| JP2023113843A5 (enExample) | ||
| JPWO2019092283A5 (enExample) | ||
| JP2023107988A5 (enExample) | ||
| JP2023166381A5 (enExample) | ||
| JP2018518201A5 (enExample) | ||
| JP2024052876A5 (enExample) | ||
| JP2006507265A5 (enExample) | ||
| JP2024149717A5 (enExample) | ||
| JP2003506347A5 (enExample) | ||
| JPWO2022158528A5 (enExample) | ||
| JPWO2021069705A5 (enExample) | ||
| JPWO2023106310A5 (enExample) | ||
| JPWO2019161213A5 (enExample) | ||
| JPWO2021049504A5 (enExample) | ||
| RU2220140C2 (ru) | Производное циклических амидов, фармацевтическая композиция и лекарственное средство, его содержащее, и способ лечения аллергического заболевания | |
| JP2023101503A5 (enExample) | ||
| JPWO2022251502A5 (enExample) | ||
| JP2007538042A5 (enExample) | ||
| JPWO2020231776A5 (enExample) | ||
| JPWO2021105334A5 (enExample) | ||
| JPWO2022047583A5 (enExample) | ||
| JPWO2021239117A5 (enExample) | ||
| JP2021095514A5 (enExample) |